Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda

Mónica L. Acevedo, Luis Alonso-Palomares, Andrés Bustamante, Aldo Gaggero, Fabio Paredes, Claudia P. Cortés, View ORCID ProfileFernando Valiente-Echeverría, View ORCID ProfileRicardo Soto-Rifo
doi: https://doi.org/10.1101/2021.06.28.21259673
Mónica L. Acevedo
1Laboratorio de Virología Molecular y Celular, Programa de Virología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luis Alonso-Palomares
1Laboratorio de Virología Molecular y Celular, Programa de Virología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrés Bustamante
1Laboratorio de Virología Molecular y Celular, Programa de Virología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aldo Gaggero
3Laboratorio de Virología Ambiental, Programa de Virología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabio Paredes
4Departamento de Epidemiología, Ministerio de Salud de Chile, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudia P. Cortés
2Clínica Santa María, Santiago, Chile
5Departamento de Medicina Centro, Facultad de Medicina, Universidad de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fernando Valiente-Echeverría
1Laboratorio de Virología Molecular y Celular, Programa de Virología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Fernando Valiente-Echeverría
  • For correspondence: rsotorifo@uchile.cl fvaliente@uchile.cl
Ricardo Soto-Rifo
1Laboratorio de Virología Molecular y Celular, Programa de Virología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ricardo Soto-Rifo
  • For correspondence: rsotorifo@uchile.cl fvaliente@uchile.cl
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background The newly described SARS-CoV-2 lineage C.37 was recently classified as a variant of interest by the WHO (Lambda variant) based on its high circulation rates in South American countries and the presence of critical mutations in the spike protein. The impact of such mutations in infectivity and immune escape from neutralizing antibodies are entirely unknown.

Methods We performed a pseudotyped virus neutralization assay and determined the impact of the Lambda variant on infectivity and immune escape using plasma samples from healthcare workers (HCW) from two centers in Santiago, Chile who received the two-doses scheme of the inactivated virus vaccine CoronaVac.

Results We observed an increased infectivity mediated by the Lambda spike protein that was even higher than that of the D614G (lineage B) or the Alpha and Gamma variants. Compared to the Wild type (lineage A), neutralization was decreased by 3.05-fold for the Lambda variant while it was 2.33-fold for the Gamma variant and 2.03-fold for the Alpha variant.

Conclusions Our results indicate that mutations present in the spike protein of the Lambda variant of interest confer increased infectivity and immune escape from neutralizing antibodies elicited by CoronaVac. These data reinforce the idea that massive vaccination campaigns in countries with high SARS-CoV-2 circulation must be accompanied by strict genomic surveillance allowing the identification of new isolates carrying spike mutations and immunology studies aimed to determine the impact of these mutations in immune escape and vaccines breakthrough.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

ANID Chile supports the authors through Fondecyt grants numbers 1190156 (R.S-R.), 1211547 (F.V.-E.) and 1181656 (A.G.)

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocol was approved by the Ethics Committee of the Faculty of Medicine at Universidad de Chile (Projects No 0361-2021 and No 096-2020) and Clinica Santa Maria (Project No132604-21). All participants signed the informed consent, and their samples were anonymized.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data will be available upon request

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted July 01, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda
Mónica L. Acevedo, Luis Alonso-Palomares, Andrés Bustamante, Aldo Gaggero, Fabio Paredes, Claudia P. Cortés, Fernando Valiente-Echeverría, Ricardo Soto-Rifo
medRxiv 2021.06.28.21259673; doi: https://doi.org/10.1101/2021.06.28.21259673
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda
Mónica L. Acevedo, Luis Alonso-Palomares, Andrés Bustamante, Aldo Gaggero, Fabio Paredes, Claudia P. Cortés, Fernando Valiente-Echeverría, Ricardo Soto-Rifo
medRxiv 2021.06.28.21259673; doi: https://doi.org/10.1101/2021.06.28.21259673

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (434)
  • Anesthesia (99)
  • Cardiovascular Medicine (948)
  • Dentistry and Oral Medicine (178)
  • Dermatology (110)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (422)
  • Epidemiology (8989)
  • Forensic Medicine (4)
  • Gastroenterology (420)
  • Genetic and Genomic Medicine (1959)
  • Geriatric Medicine (190)
  • Health Economics (402)
  • Health Informatics (1329)
  • Health Policy (660)
  • Health Systems and Quality Improvement (519)
  • Hematology (212)
  • HIV/AIDS (420)
  • Infectious Diseases (except HIV/AIDS) (10809)
  • Intensive Care and Critical Care Medicine (575)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (222)
  • Neurology (1830)
  • Nursing (110)
  • Nutrition (274)
  • Obstetrics and Gynecology (353)
  • Occupational and Environmental Health (470)
  • Oncology (999)
  • Ophthalmology (298)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (580)
  • Pharmacology and Therapeutics (276)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1904)
  • Public and Global Health (4123)
  • Radiology and Imaging (676)
  • Rehabilitation Medicine and Physical Therapy (368)
  • Respiratory Medicine (549)
  • Rheumatology (225)
  • Sexual and Reproductive Health (191)
  • Sports Medicine (177)
  • Surgery (207)
  • Toxicology (39)
  • Transplantation (109)
  • Urology (81)